Long‐term data on entecavir treatment for treatment‐naive or lamivudine‐resistant chronic hepatitis B infection in kidney transplant recipients

• Published in: Transplant infectious disease Vol. 21; no. 5; pp. e13143 - n/a
• Main Authors: Yap, Desmond Y. H., Tang, Colin, Fung, James Y. Y., Seto, Wai‐Kay, Ma, Maggie K. M., Choy, Bo Ying, Chan, Tak Mao
• Format: Journal Article
• Language: English
• Published: Denmark Wiley Subscription Services, Inc 01.10.2019
• Subjects: Adult; Antiretroviral drugs; Antiviral Agents - therapeutic use; Antiviral drugs; Chronic infection; Cirrhosis; Deoxyribonucleic acid; DNA; Drug resistance; Drug Resistance, Viral; entecavir; Female; Group dynamics; Guanine - analogs & derivatives; Guanine - therapeutic use; Hepatitis B; Hepatitis B surface antigen; Hepatitis B virus - drug effects; Hepatitis B, Chronic - drug therapy; Hepatocellular carcinoma; Humans; Kidney transplantation; Kidney Transplantation - adverse effects; Kidney transplants; Kidneys; Lamivudine; Lamivudine - pharmacology; Liver cancer; Liver cirrhosis; long‐term; Male; Middle Aged; Patients; Renal cell carcinoma; Renal function; Retrospective Studies; Stiffness; Transplant Recipients; Viremia; entecavir; hepatitis B; kidney transplantation; long-term

Introduction Entecavir (ETV) showed short‐term efficacy and safety in HBsAg‐positive kidney transplant recipients (KTRs), but long‐term data are lacking. Methodology We retrospectively reviewed 30 HBsAg‐positive KTRs who received ETV during 2007‐2017. Results Eighteen treatment‐naïve (Group I) and 1...